Overactive Bladder Treatment Market: Global Industry Research Report 2020-2027 | Envisage Research
Envisage report cover

Overactive Bladder Treatment Market - By Pharmacotherapy (Anticholinergics, SolifenacinOxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Other Anticholinergics, Mirabegron, BOTOX, Neurostimulation, Other) By Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity) By Region (North America, Europe, Asia-Pacific, RoW) - Industry Analysis, Opportunity and Forecast 2020 To 2027

Published Date: May 2021

No. of Pages: 188

Status: Published

Report Code: EMR100597

The global overactive bladder treatment market is projected to reach USD 4.95 Billion by 2027 from USD 3.97 Billion in 2020; at a CAGR of 3.2 %. Overactive bladder treatment includes various therapies used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall. This contraction leads to urgency to urinate, risen frequency of urinating, nocturia, and urge-incontinence.

Overactive bladder treatment involves several approaches ranging from medication to behavioral changes as well as a combination of both medication and behavioral changes. Bladder training and pelvic floor exercises are natural treatments for overactive bladder. On the other hand, a group of drugs called anticholinergics helps to combat the overactive bladder issue by blocking the nerve signals related to bladder muscle contraction. Rise in research and development of drugs by key players increases bladder capacity activity. This, in turn, augments the demand for drugs for use in overactive bladder treatment. Moreover, new advancements in the analytical method and the urology diagnostic technique are paving the way for early diagnosis and treatment of kidney diseases.
High prevalence of diseases such as chronic kidney disease (CKD) and diabetes, rise in geriatric population, and increase in research and development initiatives are expected to drive the global overactive bladder treatment market during the forecast period. Furthermore, introduction of new constituents of exogenous markers, rise in government funding, increase in the number of favorable initiatives for clinical laboratories, development of innovative intravesical therapies, and aggressive marketing by pharma companies are driving the global overactive bladder treatment market. Behavioral intervention is the first choice in the treatment of overactive bladder and it is commonly used among patients worldwide. Favorable reimbursements, innovative treatments, robust pipeline of drugs, and patent cliff of certain drugs are likely to provide immense growth opportunities to the overactive bladder treatment market during the forecast period. However, undesired systemic effects of the current overactive bladder treatment and side-effect of drugs are likely to be major restraints of the overactive bladder treatment market during the forecast period.

Major players operating in the global overactive bladder treatment market are AstellasPharma, Inc., Allergan, Plc, AurobindoPharma Limited, Pfizer, Inc., Teva Pharmaceutical Industries Limited, Medtronic plc, Mylan N.V., Endo International plc, and Hisamitsu Pharmaceutical Co., Inc.

Analyst Commentary

The growth of market is majorly driven by the increasing geriatric population and consequently rising prevalence of bladder overactivity, aggressive marketing strategies by pharma companies, and the development of new therapies to treat bladder overactivity. However, the undesired systemic effects caused by anticholinergics may hinder the growth of the market to a certain extent.

On the basis of pharmacotherapy, the anticholinergics segment accounted for the largest share in 2016, being the first line of medical treatment on bladder overactivity. Based on disease type, the idiopathic overactive bladder treatment segment accounted for the largest share in 2016. The high share of this segment can be attributed to its high prevalence; women are more susceptible to the condition owing to bladder muscle weakness post pregnancy and menopause.

The Rest of Asia-Pacific region is expected to witness the highest CAGR during the forecast period owing to rising prevalence of bladder over-activity, increasing geriatric population, rising healthcare expenditure, and growing awareness on overactive bladder.

Segmentation

The global overactive bladder treatment market is segmented based on pharmacotherapy, disease type, and region. Based on pharmacotherapy the market is bifurcated into Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Other Anticholinergics*, Mirabegron, BOTOX, Neurostimulation. Based on disease type the market is segmented into Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity.

Regional Analysis

Among regions, North America dominates the global overactive bladder treatment market, due to rising geriatric population suffering from urinary disorders, growing number of devices receiving regulatory approvals, increasing number of drugs receiving the FDA approval, and rising demand for new and advanced drugs for clinical tests in the region. Rising incidence of chronic kidney disease (CKD) and increasing early-stage diagnosis of diabetes and treatment of other liver diseases are driving the pharmaceutical industry in North America. This, in turn, is expected to boost the overactive bladder treatment market in North America during the forecast period. Europe is the second-largest market for overactive bladder treatment, due to presence of favorable government policies regarding development of health care infrastructure in the region.

Expansion of research and development units and pathology labs in countries of Europe is also a major factor expected to drive the market in the region during the forecast period. The market in Asia Pacific is expected to expand at a high growth rate during the forecast period, due to increase in geriatric population in the region. Increasing awareness among patients about kidney diseases and overactive urinary bladder and rising per capita health care expenditure are factors fueling the market in Asia Pacific. Additionally, economic growth of India and China is supporting the development of health care infrastructure as well as expansion of pharmaceutical companies and biotech labs in these countries. This factor is also likely to drive the overactive bladder treatment market in Asia Pacific during the forecast period.

TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Component
2.3.1. Secondary Component
2.3.1.1. Preliminary data mining
2.3.2. Primary Component
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Overactive bladder treatment Market
Chapter 5. Global Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
5.1. Global Overactive bladder treatment Market Share, By Pharmacotherapy, 2015 - 2027 (USD Billion)
5.2. Anticholinergics
5.2.1.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.2. Solifenacin
5.2.2.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.3. Oxybutynin
5.2.3.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.3.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.4. Darifenacin
5.2.4.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.4.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.5. Fesoterodine
5.2.5.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.5.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.6. Tolterodine
5.2.6.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.6.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.7. Trospium
5.2.7.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.7.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.8. Other Anticholinergics
5.2.8.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.8.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.2.9. Trospium
5.2.9.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.2.9.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.3. Mirabegron
5.3.1.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.3.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.4. BOTOX
5.4.1.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.4.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
5.5. Neurostimulation
5.5.1.1. Market Type and Projections,2015 - 2027 (USD Billion)
5.5.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
Chapter 6. Global Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027(USD Billion)
6.1. Global Overactive bladder treatment Market Share, By Disease Type, 2015 - 2027 (USD Billion)
6.1.1. Idiopathic Bladder
6.1.1.1. Market Type and Projections,2015 - 2027 (USD Billion)
6.1.1.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
6.1.2. Neurogenic Bladder
6.1.2.1. Market Type and Projections, 2015 - 2027 (USD Billion)
6.1.2.2. Market Type and Projections, by Region, 2015 - 2027 (USD Billion)
Chapter 7. Global Overactive bladder treatment Market Overview, By Geography, 2015 - 2027(USD Billion)
7.1. Global Overactive bladder treatment Market Share, By Geography, 2015 - 2027(USD Billion)
7.1.1. Market Type and projections, by Countries, 2015 - 2027 (USD Billion)
7.1.2. Market Share and CAGR Comparison, by Countries, 2020 - 2027 (%)
Chapter 8. North America Overactive bladder treatment Market Overview, By Countries, 2015 - 2027(USD Billion)
8.1. North America Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
8.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.2. North America Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
8.1.3. North America Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
8.1.4. North America Overactive bladder treatment Market Overview, By Countries, 2015 - 2027 (USD Billion)
8.1.4.1. U.S. Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
8.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.4.1.2. U.S. Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
8.1.4.1.3. U.S. Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
8.1.4.2. Canada Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
8.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.4.2.2. Canada Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
8.1.4.2.3. Canada Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
8.1.4.3. Mexico Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
8.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
8.1.4.3.2. Mexico Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
8.1.4.3.3. Mexico Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
Chapter 9. Europe Overactive bladder treatment Market Overview, By Countries, 2015 - 2027(USD Billion)
9.1. Europe Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
9.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.2. Europe Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
9.1.3. Europe Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
9.1.4. Europe Skin Care Types Market Overview, By Countries, 2015 - 2027 (USD Billion)
9.1.4.1. Germany
9.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.1.2. Germany Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
9.1.4.1.3. Germany Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027(USD Billion)
9.1.4.2. France
9.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.2.2. France Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
9.1.4.2.3. France Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027(USD Billion)
9.1.4.3. UK
9.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.3.2. UK Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
9.1.4.3.3. UK Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027(USD Billion)
9.1.4.4. Italy
9.1.4.4.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.4.2. Italy Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
9.1.4.4.3. Italy Overactive bladder treatment Market Overview, By Disease Type 2015 - 2027(USD Billion)
9.1.4.5. Spain
9.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Billion)
9.1.4.5.2. Spain Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
9.1.4.5.3. Spain Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027(USD Billion)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market Type and projections, 2015 – 2027
9.1.4.6.2. Rest of Europe Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
9.1.4.6.3. Rest of Europe Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027(USD Billion)
Chapter 10. Asia Pacific Overactive bladder treatment Market Overview, By Countries, 2015 - 2027 (USD Billion)
10.1. Asia Pacific Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
10.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.2. Asia Pacific Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
10.1.3. Asia Pacific Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
10.1.4. Asia Pacific Overactive bladder treatment Market Overview, By Countries, 2015 - 2027 (USD Billion)
10.1.4.1. India
10.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.4.1.2. India Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
10.1.4.1.3. India Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
10.1.4.2. China
10.1.4.2.1. Market Type and projections, 2015 - 2027(USD Billion)
10.1.4.2.2. China Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
10.1.4.2.3. China Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
10.1.4.3. Japan
10.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.4.3.2. Japan Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
10.1.4.3.3. Japan Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027(USD Billion)
10.1.4.4. South Korea
10.1.4.4.1. Market Type and projections, 2015 - 2027(USD Billion)
10.1.4.4.2. South Korea Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
10.1.4.4.3. South Korea Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market Type and projections, 2015 - 2027 (USD Billion)
10.1.4.5.2. Rest of Asia Pacific Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027(USD Billion)
10.1.4.5.3. Rest of Asia Pacific Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
Chapter 11. Middle East & Africa Overactive bladder treatment Market Overview, By Countries, 2015 - 2027 (USD Billion)
11.1. Middle East & Africa Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
11.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.2. Middle East & Africa Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
11.1.3. Middle East & Africa Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
11.1.4. Middle East & Africa Overactive bladder treatment Market Overview, By Countries, 2015 - 2027 (USD Billion)
11.1.4.1. GCC
11.1.4.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.4.1.2. GCC Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
11.1.4.1.3. GCC Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
11.1.4.2. South Africa
11.1.4.2.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.4.2.2. South Africa Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
11.1.4.2.3. South Africa Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market Type and projections, 2015 - 2027 (USD Billion)
11.1.4.3.2. Rest of Middle East & Africa Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
11.1.4.3.3. Rest of Middle East & Africa Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
Chapter 12. South America Overactive bladder treatment Market Overview, By Countries, 2015 - 2027 (USD Billion)
12.1. South America Overactive bladder treatment Market Overview, 2015 - 2027 (USD Billion)
12.1.1. Market Type and projections, 2015 - 2027 (USD Billion)
12.1.2. South America Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
12.1.3. South America Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
12.1.4. South America Overactive bladder treatment Market Overview, By Countries, 2015- 2026 (USD Billion)
12.1.5. Brazil
12.1.5.1. Market Type and projections, 2015 - 2027 (USD Billion)
12.1.5.2. Brazil Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
12.1.5.3. Brazil Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
12.1.6. Argentina
12.1.6.1. Market Type and projections, 2015 - 2027 (USD Billion)
12.1.6.2. Argentina Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
12.1.6.3. Argentina Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
12.1.7. Rest of South America
12.1.7.1. Market Type and projections, 2015 – 2027
12.1.7.2. Rest of South America Overactive bladder treatment Market Overview, By Pharmacotherapy, 2015 - 2027 (USD Billion)
12.1.7.3. Rest of South America Overactive bladder treatment Market Overview, By Disease Type, 2015 - 2027 (USD Billion)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2020
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Type development
Chapter 14. Key Vendor Analysis
14.1. AstellasPharma Inc.
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Product Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Allergan Plc
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Product Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. AurobindoPharma Limited
14.3.1. Company overview
14.3.2. Financial performance
14.3.3. Product Benchmarking
14.3.4. Recent initiatives
14.4. PFIZER INC
14.5. Teva Pharmaceutical Industries Limited
14.6. MEDTRONIC PLC
14.7. ENDO INTERNATIONAL PLC
14.8. Hisamitsu Pharmaceutical Co.
Chapter 15. Overactive bladder treatment Market Cost Analysis
15.1. Overactive bladder treatment Market Key Type Analysis
15.1.1. Key Type
15.1.2. Price Trend of Key Type
15.1.3. Key Suppliers of Type
15.1.4. Market Concentration Rate of Type
15.1.5. Labor Cost
Chapter 16. Sourcing Strategy and Downstream Buyers
16.1. Overactive bladder treatment Market Chain Analysis
16.2. Upstream Type Sourcing
16.3. Overactive bladder treatment Market Major Manufacturers in 2021
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Client
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Technology Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Technology Progress in Related Type
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer 
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Overactive bladder treatment Market share, By Pharmacotherapy, 2020 & 2027 (%)
10. Global Overactive bladder treatment Market share, by Anticholinergic, By Pharmacotherapy, 2015 - 2027 (USD Billion)
11. Global Overactive bladder treatment Market share, by Solifenacin, By Pharmacotherapy, 2015 - 2027 (USD Billion)
12. Global Overactive bladder treatment Market share, by Oxybutynin, By Pharmacotherapy, 2015 - 2027 (USD Billion)
13. Global Overactive bladder treatment Market share, by Darifenacin, By Pharmacotherapy, 2015 - 2027 (USD Billion)
14. Global Overactive bladder treatment Market share, by Others, By Pharmacotherapy, 2015 - 2027 (USD Billion)
15. Global Overactive bladder treatment Market share, By Disease Type, 2020 & 2027 (%)
16. Global Overactive bladder treatment Market share, by Idiopathic Bladder, By Disease Type, 2015 - 2027 (USD Billion)
17. Global Overactive bladder treatment Market share, by Neurogenic Bladder, By Disease Type 2015 - 2027 (USD Billion)
18. Global Overactive bladder treatment Market share, by region, 2020 & 2027 (%)
19. Global Overactive bladder treatment Market share, by region, 2015 - 2027(USD Billion)
20. North America Overactive bladder treatment Market, 2015 - 2027(USD Billion)
21. North America Overactive bladder treatment Market share, by Countries, 2020 & 2027 (%)
22. U.S. Overactive bladder treatment Market, 2015 - 2027(USD Billion)
23. Canada Overactive bladder treatment Market, 2015 - 2027(USD Billion)
24. Mexico Overactive bladder treatment Market, 2015 - 2027(USD Billion)
25. Europe Overactive bladder treatment Market, 2015 - 2027(USD Billion)
26. Europe Overactive bladder treatment Market share, by Countries, 2020 & 2027 (%)
27. Spain Overactive bladder treatment Market, 2015 - 2027(USD Billion)
28. UK Overactive bladder treatment Market, 2015 - 2027(USD Billion)
29. Italy Overactive bladder treatment Market, 2015 - 2027(USD Billion)
30. Germany Overactive bladder treatment Market, 2015 - 2027(USD Billion)
31. France Overactive bladder treatment Market, 2015 - 2027(USD Billion)
32. Rest of Europe Overactive bladder treatment Market, 2015 - 2027(USD Billion)
33. Asia-Pacific Overactive bladder treatment Market, 2015 - 2027(USD Billion)
34. Asia-Pacific Overactive bladder treatment Market share, by Countries, 2020 & 2027 (%)
35. China Overactive bladder treatment Market, 2015 - 2027(USD Billion)
36. India Overactive bladder treatment Market, 2015 - 2027(USD Billion)
37. Australia Overactive bladder treatment Market, 2015 - 2027(USD Billion)
38. Japan Overactive bladder treatment Market, 2015 - 2027(USD Billion)
39. Rest of Asia-Pacific Overactive bladder treatment Market, 2015 - 2027(USD Billion)
40. Middle East & Africa Overactive bladder treatment Market, 2015 - 2027(USD Billion)
41. Middle East & Africa Overactive bladder treatment Market share, by Countries, 2020 & 2027 (%)
42. GCC Overactive bladder treatment Market, 2015 - 2027(USD Billion)
43. South Africa Overactive bladder treatment Market, 2015 - 2027(USD Billion)
44. Rest Of Middle East & Africa Overactive bladder treatment Market, 2015 - 2027(USD Billion)
45. South America Overactive bladder treatment Market, 2015 - 2027(USD Billion)
46. Brazil Overactive bladder treatment Market, 2015 - 2027(USD Billion)
47. Mexico Overactive bladder treatment Market, 2015 - 2027(USD Billion)
48. Argentina Overactive bladder treatment Market, 2015 - 2027(USD Billion)
49. Rest Of South America Overactive bladder treatment Market, 2015 - 2027(USD Billion)

List of Tables

1. Impact of Market drivers
2. Impact of Market restraints
3. Global Overactive bladder treatment Market, 2015-2027 (USD Billion)
4. Overactive bladder treatment requirement, by country, 2015-2027, (USD Billion)
5. North America Overactive bladder treatment Market, By Pharmacotherapy, 2015-2027 (USD Billion)
6. North America Overactive bladder treatment Market, By Disease Type, 2015-2027 (USD Billion)
7. Europe Overactive bladder treatment Market, By Pharmacotherapy, 2015-2027 (USD Billion)
8. Europe Overactive bladder treatment Market, By Disease Type, 2015-2027 (USD Billion)
9. Asia Pacific Overactive bladder treatment Market, By Pharmacotherapy, 2015-2027 (USD Billion)
10. Asia Pacific Overactive bladder treatment Market, By Disease Type, 2015-2027 (Revenue, USD Billion)
11. Middle East & Africa Overactive bladder treatment Market, By Pharmacotherapy, 2015-2027 (USD Billion)
12. Middle East & Africa Overactive bladder treatment Market, By Disease Type, 2015-2027 (USD Billion)
13. South America Overactive bladder treatment Market, By Pharmacotherapy, 2015-2027 (USD Billion)
14. South America Overactive bladder treatment Market, By Disease Type, 2015-2027 (USD Billion)
15. Global Overactive bladder treatment Market, Company Market Share, 2020 - 2027 (%)
16. AstellasPharma Inc. : Disease Type Benchmarking
17. AstellasPharma Inc. : Financial Performance
18. Allergan Plc: Disease Type Benchmarking
19. Allergan Plc: Financial Performance
20. AurobindoPharma Limited : Disease Type Benchmarking
21. AurobindoPharma Limited : Financial Performance
22. PFIZER INC :Disease Type Benchmarking
23. PFIZER INC : Financial Performance
24. Best Metal Disease Types: Disease Type Benchmarking
25. Best Metal Disease Types: Financial Performance
26. MEDTRONIC PLC : Disease Type Benchmarking
27. MEDTRONIC PLC : Financial Performance
28. ENDO INTERNATIONAL PLC .: Disease Type Benchmarking
29. ENDO INTERNATIONAL PLC .: Financial Performance
30. MYLAN N.V., : Disease Type Benchmarking
31. MYLAN N.V., : Financial Performance

The Leading Key Players in Overactive Bladder Treatment Market

AstellasPharma Inc.
Allergan
Plc
AurobindoPharma Limited
Pfizer Inc.
Teva Pharmaceutical Industries Limited
Medtronic plc
Mylan N.V.
Endo International plc
Hisamitsu Pharmaceutical Co. Inc.